BYSI vs. MGTA, MEIP, KMDA, ANNX, ERAS, KRRO, LRMR, FULC, VERV, and NGNE
Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Magenta Therapeutics (MGTA), MEI Pharma (MEIP), Kamada (KMDA), Annexon (ANNX), Erasca (ERAS), Korro Bio (KRRO), Larimar Therapeutics (LRMR), Fulcrum Therapeutics (FULC), Verve Therapeutics (VERV), and Neurogene (NGNE). These companies are all part of the "medical" sector.
BeyondSpring (NASDAQ:BYSI) and Magenta Therapeutics (NASDAQ:MGTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.
BeyondSpring has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Magenta Therapeutics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500.
BeyondSpring's return on equity of 0.00% beat Magenta Therapeutics' return on equity.
In the previous week, BeyondSpring had 2 more articles in the media than Magenta Therapeutics. MarketBeat recorded 2 mentions for BeyondSpring and 0 mentions for Magenta Therapeutics. BeyondSpring's average media sentiment score of 1.85 beat Magenta Therapeutics' score of 0.95 indicating that BeyondSpring is being referred to more favorably in the media.
BeyondSpring received 28 more outperform votes than Magenta Therapeutics when rated by MarketBeat users. Likewise, 66.79% of users gave BeyondSpring an outperform vote while only 57.09% of users gave Magenta Therapeutics an outperform vote.
BeyondSpring has higher revenue and earnings than Magenta Therapeutics.
40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 47.5% of Magenta Therapeutics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 15.2% of Magenta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
BeyondSpring beats Magenta Therapeutics on 9 of the 11 factors compared between the two stocks.
Get BeyondSpring News Delivered to You Automatically
Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BeyondSpring Competitors List
Related Companies and Tools
